

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the “Shanghai Junshi Biosciences Co., Ltd.* Announcement on the Convening of the 2023 Third Quarterly Results Briefing” published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 7 November 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong, Dr. Zou Jianjun and Dr. Wang Gang as executive directors; Dr. Feng Hui, Mr. Tang Yi and Dr. Li Xin as non-executive directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive directors.

* *For identification purpose only*

Shanghai Junshi Biosciences Co., Ltd.*
Announcement on the Convening of
the 2023 Third Quarterly Results Briefing

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Importance Notice:

- Time of the briefing: 9:00-10:00, 15 November 2023 (Wednesday)
- Venue of the briefing: SSE Roadshow Center (<http://roadshow.sseinfo.com>)
- Mode of the briefing: Online interactive text
- Investors are invited to send questions of interest to the email of Shanghai Junshi Biosciences Co., Ltd.* (the “**Company**”) (info@junshipharma.com) from 8 November 2023 (Wednesday) to 16:00, 14 November 2023 (Tuesday). The Company will respond to questions that are of general concern to investors at the briefing.

The Company has published the 2023 third quarterly report on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 28 October 2023. In order to facilitate its communication with investors, with the support from the Shanghai Stock Exchange, the Company plans to convene the 2023 third quarterly results briefing at 9:00-10:00, 15 November 2023 (Wednesday). Investors are welcome to attend.

I. Type of the Briefing

This investor briefing will be held in the form of online interactive text. The Company will interact and communicate with investors with regard to the operating results and specific financial indicators for the third quarter of 2023. Questions that are

of general concern to investors will be answered subject to restrictions under the information disclosure rules.

II. Time, Mode and Venue of the Briefing

(I) Time of the briefing: 9:00-10:00, 15 November 2023 (Wednesday)

(II) Venue of the briefing: SSE Roadshow Center (<http://roadshow.sseinfo.com>)

(III) Mode of the briefing: Online interactive text

III. Attendees

Attendees of the briefing include: Mr. Ning Li (Executive Director and General Manager), Mr. Chun Zhang (Independent Non-Executive Director), Mr. Baohong Xu (Financial Director), and Ms. Yingge Chen (Secretary of the Board of Directors) (subject to changes in case of any special circumstances).

IV. Ways of Participation by Investors

(I) Investors may access the website of the SSE Roadshow Center (<http://roadshow.sseinfo.com>) at 9:00-10:00, 15 November 2023 (Wednesday) to participate the briefing online. The Company will respond to the questions of the investors in a timely manner.

(II) Investors are invited to ask questions through the "Pre-collection of Questions" header (<http://roadshow.sseinfo.com/questionCollection.do>) located at the homepage of the SSE Roadshow Center website or send questions to the Company's email (info@junshipharma.com) in advance from 8 November 2023 (Wednesday) to 16:00, 14 November 2023 (Tuesday). The Company will respond to questions that are of general concern to investors at the briefing.

V. Contact Details for the Briefing

Contact Department: Securities Department

Contact Tel.: 021-61058800-1153

Contact Email: info@junshipharma.com

VI. Others Matters

Upon the convening of the investor briefing, investors may review the convening details and key contents of the investor briefing at the website of the SSE Roadshow Center (<http://roadshow.sseinfo.com/>).

Notice is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

8 November 2023

** For identification purpose only*